Trial abstract · §3
EPI-RU-ELDERLY — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| All-cause mortality and functional indices in an older cohort | The Institute has not been able to obtain a protocol, a randomisation procedure or an analysis plan for the reports circulated under this name and grades all claims in this programme very low certainty | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Epithalon from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| No controlled safety dataset | — | — | None of adequate quality exists |
| Telomerase induction | — | — | If the proposed telomerase mechanism operated as described, the implications for neoplasia would require careful study; none has been performed |
Compound Evidence Institute · CEI-TR-0110/3 · https://compoundevidence.com/trials/epi-ru-elderly/results/ · retrieved 30 July 2026